influenza-2016_posters-accepted-abstracts

4 / 25

Volume 4, Issue 6(Suppl) J Infect Dis Ther
ISSN: 2332-0877 JIDT, an open access journal
Page 50
Notes:
Influenza 2016
September 12-13, 2016
conferenceseries.com
Influenza
September 12-13, 2016 Berlin, Germany
2nd International Conference on
Development and optimization of the assay for screening the compounds disrupting protein-protein
interaction in influenza A polymerase
Milan Kozisek1, Hejdanek Jakub1, 2 , Machara Ales2 and Konvalinka Jan 1, 2
1Academy of Sciences of the Czech Republic, Czech Republic
2Charles University, Czech Republic
Influenza virus causes severe respiratory infections in birds and mammals that are responsible for up to half a million deaths of
human beings worldwide each year. Two targets of therapeutic interventions in influenza life cycle, viral neuraminidase and M2
channel are exploited in treatment. However, the recent emergence of new pandemic type along with increasing resistance against
approved drugs has urged the need for a new drug target and design of its inhibitor. Recently, an interesting protein-protein interaction
between two subunits of viral polymerase PA and PB1 has been identified as a new promising drug target. The fact that relatively
few residues drive the binding and the binding interface is highly conserved presents an intriguing possibility to identify antiviral
lead compounds effective against all subtypes of influenza A virus. In our laboratory, we have expressed and purified recombinant
C-terminal part of the PA polymerase subunit with GST at its N-terminus from pandemic isolate A/California/07/2009 H1N1. The
biotinylated peptide representing the N-terminal interacting part of PB1 subunit was synthesized by using a solid-phase synthesizer.
The protein-protein interaction between PA and PB1 was then kinetically characterized using a surface Plasmon resonance (SPR).
Finally, we developed and optimized an assay for screening the compounds disrupting the interaction between polymerase subunits,
based on the AlphaScreen technology and validated the assay that has the potential to be used in drug discovery.
Biography
Milan Kozisek is a Senior Scientist at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague. He has completed his PhD
in 2010. He is an author of 29 papers in peer-reviewed international journals and 4 patents.
Milan Kozisek et al., J Infect Dis Ther 2016, 4:6(Suppl)